A self-controlled, naturalistic study of selective serotonin reuptake inhibitors versus tricyclic antidepressants

Psychotherapy and Psychosomatics

Volumn 72, Issue 2, 2003, Pages 95-101

  Faravelli, C ^a,b   Cosci, F ^a   Ciampelli, M ^a   Scarpato, M A ^a   Spiti, R ^a   Ricca, V ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Dipto Sci Neurologiche P   (Italy)

Author keywords

Effectiveness; Naturalistic approach; Selective serotonin reuptake inhibitors; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOOD DISORDER; OUTPATIENT; PRIORITY JOURNAL; RATING SCALE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; FEMALE; HUMANS; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; MOOD DISORDERS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0037221928     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068689     Document Type: Article

References (66)

1. Pursuel M, Perry P: Fiscal Year 1994-1995 Annual Report of Drug Ranking by Prescription Number. Des Moines, Iowa Medicaid Drug Utilization Review Commission, 1995.
2. Hollister LE: Current antidepressant drugs: Their clinical use. Drugs 1981;22:129-152.
3. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, Mason J: Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability. BMJ 1993;306:683-687.
4. Stokes PE: Fluoxetine: A five-year review. Clin Ther 1993;15:216-243.
5. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D: Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53.
6. Mitchell J, Greenberg J, Finch K, Kovach J, Kipp L, Shainline M, Jordan N, Anderson C: Effectiveness and economic impact of antide-pressant medication: A review. Am J Manag Care 1997;3:323-330.
7. Steffens DC, Krishnan KR, Helms MJ: Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis. Depress Anxiety 1997;6:10-18.
8. Rosholm JU, Gram LF, Isacsson G, Hallas J, Bergman U: Changes in the pattern of antide-pressant use upon the introduction of the new antidepressants: A prescription database study. Eur J Clin Pharmacol 1997;52:205-209.
9. Nurnberg HG, Thompson PM, Hensley PL: Antidepressant medication change in a clinical treatment setting: A comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry 1999;60:574-579.
10. Isacsson G, Boethius G, Henriksson S, Jones JK, Bergman U: Selective serotonin reuptake inhibitors have broadened the utilization of antidepressant treatment in accordance with recommendation. Findings from a Swedish prescription database. J Affect Disord 1999;53:15-22.
11. Anderson IM: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36.
12. Demyttenaere K, Haddad P: Compliance with antidepressant therapy and antidepressant discontinuation symptoms. Acta Psychiatr Scand 2000;101:50-56.
13. Keller MB: Citalopram therapy for depression: A review of 10 years of European experience and data from US clinical trials. J Clin Psychiatry 2000;61:896-908.
14. Mendelewicz J, Lecrubier Y: Antidepressant selection: Proceeding from a TCA/SSRI Consensus Conference. Acta Psychiatr Scand Suppl 2000;403:5-8.
15. Peretti S, Judge R, Hindmarch I: Safety and tolerability considerations: Tricyclic antidepressants versus selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2000;403:17-25.
16. Zohar J, Westenberg HG: Anxiety disorders: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2000;403:39-49.
17. Danish University Antidepressant Group: Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986;90:131-138.
18. Danish University Antidepressant Group: Paroxetine: A selective serotonin reuptake inhibitors showing better tolerance, but weaker antidepressant effect that clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299.
19. Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR: The short- and long-term efficacy of paroxetine HCl. A. Data from a 6-week double-blind parallel-design trial vs. imipramine and placebo. Psychopharmacol Bull 1989;25:267-271.
20. Barbui C, Hotopf M: Amitriptyline vs. the rest: Still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001;178:129-144.
21. Ottevanger EA: The efficacy of fluvoxamine in patients with severe depression. Br J Clin Res 1991;2:125-132.
22. Pande AC, Sayler ME: Fluoxetine - A clinical and research update: Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 1993;8:243-245.
23. Hotopf M, Lewis G, Normand C: Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry 1996;168:404-409.
24. Anderson IM: SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7:11-17.
25. Bech P, Cialdella P, Haigh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD: Meta-analysis of randomized controlled trials of fluoxetine versus placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000;176:421-428.
26. Montgomery SA: A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 2001;16:169-178.
27. Baldessarini RJ, Ghaemi SN, Viguera AC: Tolerance in antidepressant treatment. Psychother Psychosom 2002;71:177-179.
28. Fava M, Schmidt ME, Zhang S, Gonzales J, Rante NJ, Judge R: Treatment approaches to major depressive disorder relapse. 2. Reinitiation of antidepressant treatment. Psychother Psychosom 2002;71:195-199.
29. Endicott J, Schwartz GE, Lee JH: Classification in patient selection and description; in Prien RF, Robinson DS (eds): Clinical Evaluation of Psychotropic Drugs. New York, Raven Press, 1994, pp 69-83.
30. Feinstein A: An additional basic science for clinical medicine. 2. The limitations of randomized trials. Ann Intern Med 1983;99:544-550.
31. Simon GE, Von Korff M, Heilingenstein JH, Revicki DA, Grothaus L, Katon W, Wagner EH: Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs. tricyclic antidepressants. JAMA 1996;275:1897-1902.
32. Thase ME: How should efficacy be evaluated in randomized clinical trials of treatments for depression? J Clin Psychiatry 1999;60:23-31.
33. Perry PJ: Pharmacotherapy for major depression with melancholic features: Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996;39:1-6.
34. Panteleeva GP, Abramova LI, Korenev AN: Selective serotonin reuptake inhibitors in the therapy of various types of endogenous depressions. Zh Nevrol Psikhiatr Im S S Korsakova 2000;100:36-41.
35. Walters G, Reynolds CF 3rd, Mulsant BH, Pol-lock SG: Continuation and maintenance pharmacotherapy in geriatric depression: An open-trial comparison of paroxetine and nortiptyline and patients older than 70 years. J Clin Psychiatry 1999;60(suppl 20):21-25.
36. Thompson SG, Pocock SJ: Can a meta-analysis be trusted? Lancet 1991;338:1127-1130.
37. Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD: A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994;182:547-551.
38. Hotopf M, Hardy R, Lewis G: Discontinuation rates of SSRIs and tricyclic antidepressants. A meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997;170:120-127.
39. Klein DF: Clinical psychopharmacologic practice. The need for developing a research base. Arch Gen Psychiatry 1993;50:491-494.
40. Stewart A: Choosing an antidepressant: Effectiveness-based pharmacoeconomics. J Affect Disord 1998;48:125-133.
41. Fava GA: Long-term treatment with antidepressant drugs: The spectacular achievements of propaganda. Psychother Psychosom 2002;71:127-132.
42. Hollister LE, Jones JK, Fisher S: Post-marketing surveillance of drug; in Prien RF, Robonson DS (eds): Clinical Evaluation of Psychotropic Drugs. New York, Raven Press, 1994, pp 217-235.
43. Faravelli C, Servi P, Arends JA, Strik WK: Number of symptoms, quantification, and qualification of depression. Compr Psychiatry 1996;5:307-315.
44. Faravelli C, Bartolozzi D, Cimminiello L, Cec-chi C, Cosci F, D'Adamo D, Di Matteo C, Di Primio C, Fabbri C, Lo Iacono B, Paionni A, Perone A, Rosi S, Scarpato MA, Serena A, Taberna A: The Florence Psychiatry Interview. Int J Methods Psychiatr Res 2002;10:157-171.
45. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
46. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
47. Dillon DJ, Gorman JM, Liebowitz MR, Fyer AJ, Klein DF: Measurement of lactate-induced panic and anxiety. Psychiatry Res 1987;20:97-105.
48. Sheehan DV: The Anxiety Disease. New York, Scribners, 1983, pp 144-153.
49. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale Brown Obsessive Compulsive Scale. 1. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011.
50. Faravelli C, Paterniti S: The assessment of agoraphobic attitudes. Eur Psychiatry 1994;9:223-228.
51. Beigel A, Murphy DL: Assessing clinical characteristics of the manic state. Am J Psychiatry 1971;128:688-694.
52. Montgomery SA, Asberg M: A new depression scale designed to be more sensitive to change. Br J Psychiatry 1979;43:382-389.
53. Guy W: ECDEU Assessment Manual for Psychopharmacology. Washington, Department of Health, Education and Welfare, 1976, pp 217-222.
54. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
55. Altamura AC, Casacchia M, Cassano GB, et al: Linee guida per il trattamento farmacologico dell'episodio depressivo. Consensus Conference, Firenze, 24-25 Settembre 1993. Riv Psichiatria 1994;29:1-24.
56. American Psychiatric Association: Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993;150:1-26.
57. Guidelines on psychotropic drugs for the EC: Clinical investigation of medicinal products in the treatment of generalized anxiety disorder, panic disorder and obsessive-compulsive disorder. Eur Neuropsychopharmacol 1995;5:151-155.
58. Katon W, Von Korff M, Lin E, Simon G, Walker E, Bush T, Robinson P, Russo J: Collaborative management to achieve treatment guidelines. JAMA 1995;273:1026-1032.
59. Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, Schatzberg AF, Koran LM, Keller MB, Russell JM, Hirshfeld RM, LaVange LM, Klein DN, Fawcett J, Harrison W: Double-blind switch study of imipramine or setraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002;59:233-239.
60. Cornwall PL: Naturalistic treatment study of depression in general practice. BMJ 1999;319:921.
61. Donoghue J: Antidepressant use patterns in clinical practices: Comparison among tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2000;101:57-61.
62. Degner D, Grohmann R, Bleich S, Ruther E: New antidepressant drugs. What side effects and interactions are to be expected? MMW Fortschr Med 2000:142:35-38
63. Trindade E, Menon D, Topfer LA, Coloma C: Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressant: A meta-analysis. CMAJ 1998;159:1245-1252.
64. Anderson IM, Tomenson BM: Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis. BMJ 1995;310:1433-1438.
65. Anderson IM, Tomenson BM: The efficacy of selective serotonin reuptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-249.
66. Otto MW, Nierenberg AA: Assay sensitivity, failed trials, and the conduct of science. Psychother Psychosom 2002;71:241-243.